Role of Regulatory T Cells in Pathogenesis of Primary IgA Nephropathy

计划入组 45 人 · 首次发布于 2007 年 8 月 28 日

A Trial of HRS-5965 Tablets in Primary IgA Nephropathy

计划入组 123 人 · 首次发布于 2023 年 11 月 18 日

The MIMIGA Study is a Randomized, Double-blind, Placebo-controlled Crossover Trial Evaluating the Safety and Efficacy of SCFA vs. Placebo. Administered Orally Once Daily With Standard Care, it Aims to Prevent CKD Progression in Biopsy-proven IgA Nephropathy by Modulating the Gut Microbiome.

计划入组 120 人 · 首次发布于 2026 年 8 月 6 日

ImmTOR + IgA protease (autoimmune dusease/IgA nephropathy)

sIgA immunotherapy (Secretory IgA)

anti-proliferation-inducing ligand humanised IgG4 monoclonal antibody (IgA nephropathy)

PRIMARY PHARMACEUTICALS, INC.

United States

PRIMARY HEALTH CARE CORPORATION

Qatar

Southcoast Center For Primary & Specialty Care

United States

Renalys Pharma Completes Enrollment in Phase III Trial of Sparsentan for IgA Nephropathy in Japan

FDA Grants Accelerated Approval to Novartis' Fabhalta (Iptacopan) for IgA Nephropathy

Taiwan TFDA Approves Nefecon for Primary IgA Nephropathy Treatment